RKVTF (Rakovina Therapeutics) Days Payable: 0.00 (As of Mar. 2026)


RKVTF Rakovina Therapeutics Inc RKVTF
32 GF Score
Price $0.09
! 1 Warning Sign
View Full Analysis

What is Rakovina Therapeutics Days Payable?

Rakovina Therapeutics RKVTF 32 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates RKVTF with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 703 Biotechnology companies, Rakovina Therapeutics ranks worse than 142247.37% on this metric.

Rakovina Therapeutics's average Accounts Payable for the three months ended in Mar. 2026 was $0.99 Mil. Rakovina Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2026 was $0.00 Mil.

The historical rank and industry rank for Rakovina Therapeutics's Days Payable or its related term are showing as below:

RKVTF's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.76
* Ranked among companies with meaningful Days Payable only.

Rakovina Therapeutics's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

Rakovina Therapeutics Days Payable Historical Data

* Premium members only.

The historical data trend for Rakovina Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rakovina Therapeutics Days Payable Chart

Rakovina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Days Payable
0.00 0.00 0.00 0.00 0.00

Rakovina Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RKVTF vs VRTX, REGN, ALNY: Days Payable Comparison

For the Biotechnology subindustry, Rakovina Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rakovina Therapeutics Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rakovina Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Rakovina Therapeutics's Days Payable falls into.


RKVTF
32GF Score
Rakovina Therapeutics Inc RKVTF
Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rakovina Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Rakovina Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

Days Payable (A: Dec. 2025 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2024 ) + Accounts Payable (A: Dec. 2025 )) / count ) / Cost of Goods Sold (A: Dec. 2025 )*Days in Period
=( (0.284 + 0.871) / 2 ) / 0*365
=0.5775 / 0*365
=N/A

Rakovina Therapeutics's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

Days Payable (Q: Mar. 2026 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Dec. 2025 ) + Accounts Payable (Q: Mar. 2026 )) / count ) / Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=( (0.871 + 1.112) / 2 ) / 0*365 / 4
=0.9915 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
Rakovina Therapeutics (RKVTF) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Rakovina Therapeutics and its competitors. According to the industry distribution chart, Rakovina Therapeutics ranks #999999 out of 703 companies in the Biotechnology industry.
Is Rakovina Therapeutics' Days Payable too high?
Rakovina Therapeutics' current Days Payable is 0.00. Based on the distribution chart, Rakovina Therapeutics ranks #999999 out of 703 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Rakovina Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Rakovina Therapeutics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Rakovina Therapeutics ranks #999999 out of 703 companies for Days Payable. This places Rakovina Therapeutics in the lower half of its industry. The industry median Days Payable is 113.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Rakovina Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rakovina Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rakovina Therapeutics stock overvalued right now?
Rakovina Therapeutics (RKVTF) has a current Days Payable of 0.00. The current Days Payable is 0.00. Rakovina Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Rakovina Therapeutics (RKVTF), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rakovina Therapeutics Business Description

Other Exchanges 7JO0:GermanyRKV:Canada
Address 999 West Broadway, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Rakovina Therapeutics Inc is a biopharmaceutical research company focused on the development of cancer treatments. Its work is based on technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, it can review and optimize drug candidates at a greater pace. The company has established a pipeline of distinctive DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Its drug development pipeline consists of candidates like kt-5000AI, kt-2000AI, and kt-3283, targeting solid tumours and PARP-resistant adult and childhood cancers.
32GF Score

Get the complete analysis for RKVTF

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.09
Price